Medpace Holdings, Inc. (MEDP) Debt to Equity Ratio: 0.55
Is Medpace Holdings, Inc.’s debt to equity ratio high or low?
Medpace Holdings, Inc.'s debt to equity ratio of 0.55 is 89% above its 5-year average of 0.29, near the high end of its 5-year range (0.14–0.55).
As of Saturday, June 20, 2026. 50.68% above its 12-month average of 0.36.
MEDP Debt to Equity Ratio Chart
MEDP Average Debt to Equity Ratio Chart
MEDP Current vs Average Debt to Equity Ratio Chart
MEDP Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.55
DEBT TO EQUITY RATIO AVG TTM
0.36
DEBT TO EQUITY RATIO AVG 3Y
0.37
DEBT TO EQUITY RATIO AVG 5Y
0.29
DEBT TO EQUITY RATIO AVG 10Y
0.32
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+50.68%
CURRENT VS 3Y AVG
+49.66%
CURRENT VS 5Y AVG
+88.57%
CURRENT VS 10Y AVG
+69.47%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.14B | 0.55 | 0.36 | 0.37 | 0.29 |
| Solventum Corporation (SOLV)vs › | $13.06B | 1.00 | 1.85 | 1.11 | 0.74 |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 0.03 | 0.03 | 0.03 | 0.03 |
| DaVita Inc. (DVA)vs › | $13.34B | -23.12 | 55.08 | 35.65 | 25.99 |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 0.34 | 0.33 | 0.35 | 0.36 |
| Revvity, Inc. (RVTY)vs › | $11.16B | 0.48 | 0.45 | 0.51 | 0.56 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 3.23 | 2.45 | 1.88 | 1.68 |
| Baxter International Inc. (BAX)vs › | $10.27B | 1.63 | 1.78 | 2.05 | 1.83 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 0.52 | 0.52 | 0.55 | 0.69 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 0.59 | 0.54 | 0.51 | 0.54 |
Financial Health
Debt/Equity
0.55
Current Ratio
0.74
Medpace Holdings, Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Medpace Holdings, Inc. (MEDP)?
- The debt to equity ratio for MEDP stock is 0.55.
- Is Medpace Holdings, Inc.'s debt to equity ratio high or low?
- Medpace Holdings, Inc.'s debt to equity ratio of 0.55 is 89% above its 5-year average of 0.29, near the high end of its 5-year range (0.14–0.55).
- What is the TTM average debt to equity ratio for Medpace Holdings, Inc. (MEDP)?
- The TTM average debt to equity ratio for MEDP stock is 0.36.
- What is the 3Y average debt to equity ratio for Medpace Holdings, Inc. (MEDP)?
- The 3Y average debt to equity ratio for MEDP stock is 0.37.
- What is the 5Y average debt to equity ratio for Medpace Holdings, Inc. (MEDP)?
- The 5Y average debt to equity ratio for MEDP stock is 0.29.
- What is the 10Y average debt to equity ratio for Medpace Holdings, Inc. (MEDP)?
- The 10Y average debt to equity ratio for MEDP stock is 0.32.
Medpace Holdings, Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.55 |
| 2024-12-31 | 0.18 |
| 2023-12-31 | 0.25 |
| 2022-12-31 | 0.49 |
| 2021-12-31 | 0.14 |
| 2020-12-31 | 0.14 |
| 2019-12-31 | 0.06 |
| 2018-12-31 | 0.14 |
| 2017-12-31 | 0.44 |
| 2016-12-31 | 0.27 |
| 2015-12-31 | 0.91 |
| 2014-12-31 | 1.22 |
| 2013-12-31 | 0.00 |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle